The LEPR gene is a key focus in obesity research, with studies linking its polymorphisms to various diseases like polycystic ovarian syndrome and energy intake disorders. This study aims to investigate the prevalence of the rs2025804 variant within LEPR and its distribution among healthy individuals across diverse ethnic groups in Iran.

The frequency of the rs2025804 genotype in the LEPR gene was analyzed in 1142 healthy adults representing different ethnicities in Iran. Saliva samples were randomly collected, and genomic DNA was extracted using a standard kit. Genotyping was performed using the Illumina Infinium Global Screening Array-24 BeadChip. Genotype and allele frequencies were calculated using SPSS software version 22, with a 95% confidence level.

Among the 1142 individuals surveyed across 29 provinces, 683 (59.81%) had genotype AA, 408 (35.73%) had genotype AG, and 51 (4.47%) had genotype GG. The allele frequencies for A and G were found to be 1774 (77.67%) and 510 (22.32%), respectively. Our findings show a unique allele distribution compared to other ethnic groups, with genotype AA being the most prevalent (59.81%), followed by AG (35.73%) and GG (4.47%). Allele frequencies are A (77.67%) and G (22.32%).

This study documents the genotype and allele frequencies of rs2025804 in the LEPR gene among healthy Iranians for the first time. Routine LEPR genotyping could potentially serve as a screening tool for obesity-related disorders, given these results. This enhances our understanding of genetic diversity and holds promise for targeted healthcare interventions.

Laparoscopic promontofixation is often considered the preferred approach for the treatment of significant apical pelvic organ prolapse (POP). Obesity is an established risk factor for pelvic organ prolapse (POP), and obese patients may constitute a substantial portion of those seeking care for uterovaginal prolapse. Our aim was to evaluate the impact of body mass index on perioperative complications and long-term outcomes of this procedure.

This is a single center retrospective cohort study. All patients who underwent laparoscopic sacrohysteropexy/sacrocolpopexy, between July 2011 and December 2021 were evaluated. The study population was divided into three groups, according to Body mass index (BMI) at time of surgery.

Altogether 246 patients were included: 145 in group 1 (mean BMI 21.9 ± 2), 88 patients in group 2 (mean BMI 27.1 ± 1), and 13 patients in group 3 (mean BMI 33.0 ± 3). LSH was more frequent than LSC in all groups. The overall perioperative complications rate was 6.3 %. There were no differences in operative details and rates of perioperative complications between the groups. During follow-up period, 30 patients (12.2 %) presented with prolapse recurrence (objective and/or subjective). The rates of prolapse recurrence, as well as long-term complications, were similar between the groups. Similarly, the groups did not differ in postoperative functional results except for postoperative constipation (group 1--14.5 %, group 2--23.8 %, group 3--25 %, p = 0.001).

Laparoscopic sacrohysteropexy/sacrocolpopexy is associated with low rates of perioperative and long- term complications. We did not find a difference in rates of complications and/ or long-term outcomes, between different weights groups.

This meta-analysis is aimed to verify the effectiveness and safety of Photobiomodulation (PBM) on body measurements, metabolic indicators, and inflammation indicators in obese patients across randomized controlled trials with various comparators.

From the inception of databases to January 5, 2025, we conducted a comprehensive literature search across PubMed, OVID, Cochrane, Embase, Web of Science, LILACS, Chinese Scientific Journals Database (VIP), Wanfang and China National Knowledge Infrastructure (CNKI). Two reviewers independently performed the search, extracted data, and assessed study quality based on predefined inclusion and exclusion criteria. Data analysis was carried out using Review Manager 5.4 software. The reporting and quality assessment of this review study was guided by the PRISMA and AMSTAR.

Eleven RCTs with a total of 569 patients were included in meta-analysis. The pooled data revealed that PBM demonstrated significantly improvements in body anthropometric measurements, such as waistline [MD = - 7.28, 95% CI (- 9.97 to - 5.67), p < 0.00001], weight [MD = - 3.54, 95% CI (- 5.97 to - 1.11), p < 0.00001], BMI [MD = - 1.18, 95% CI (- 1.93 to - 0.43), p = 0.002]. PBM also showed potential in the reduction of CRP [MD = - 0.99, 95% CI (- 1.17 to - 0.82), p < 0.00001], as well as in TC, and HOMA-IR, which is [MD = - 23.01, 95% CI (- 31.68 to - 14.35), p < 0.00001] and [MD = - 0.46, 95% CI (- 0.73 to - 0.20), p = 0.0007] respectively. No significant differences were found in reducing WHR [MD = - 0.05, 95% CI (- 0.1 to 0.00), p = 0.05], fat mass percentage [MD = - 0.28, 95% CI (- 1.25 to 0.69), p = 0.57] and insulin [MD = - 1.98, 95% CI (- 4.20 to 0.23), p = 0.08].

The results of our study suggest that PBM may offer potential benefits for treating obesity, showing some improvements in key indicators such as BMI, weight, waist circumference, CRP, TC, and HOMA-IR compared to exercise, dietary changes, and sham PBM. However, further theoretical exploration of PBM is needed, and multi-center, large-scale trials with longer follow-up durations and demographic range are necessary to confirm and validate the findings of our study. REGISTRATION NUMBER: CRD42024532988.

Obesity is a substantial concern in oncology, influencing cancer characteristics and treatment outcomes. This study investigated whether obesity contributes to increased 30-day mortality and morbidity in patients receiving anticancer therapy. In this multicenter retrospective cohort study, patients with cancer were categorized as either normal weight or obese and analyzed based on demographics, cancer types, treatment modalities, and 30-day posttreatment mortality and morbidity rates. Statistical comparisons were performed to determine associations between obesity, treatment type, and clinical outcomes. Among 1635 patients, 46.6% (n = 760) were of normal weight and 53.4% (n = 875) were obese. Obesity was more prevalent among female patients, while 60.4% of male patients were of normal weight (P = 0.001). Substantial associations have been found between obesity and specific cancers, including colorectal cancer, lymphoma, head and neck cancer, and sarcoma. Chemotherapy was more frequently administered to patients with obesity (62.5%, P = 0.001), while hormonal therapy was predominantly administered to patients with normal weight (81.8%). Patients with normal weight exhibited a higher 30-day mortality rate (74.5%, P = 0.05), although morbidity rates did not differ substantially between the weight groups. Obesity is associated with specific cancer types and influences treatment selection, but it does not independently increase the incidence of short-term treatment complications. These findings suggest that the effect of obesity is more prominent in terms of cancer type and treatment choice than in predicting short-term morbidity. Further studies are warranted to elucidate the long-term effects of obesity on cancer outcomes.

Several studies have demonstrated significant phenotypic and genetic correlations between body mass index (BMI) and brain morphological traits derived from structural magnetic resonance imaging (sMRI). We use the sMRI, BMI, and genetic data collected by the UK Biobank to systematically compute the genetic correlations between area, volume, and thickness measurements of hundreds of brain structures on one hand, and BMI on the other. In agreement with previous literature, we find many such measurements to have negative genetic correlation with BMI. We then dissect the molecular mechanisms underlying such correlations using brain eQTL data and summary-based Mendelian randomization, thus producing an atlas of genes whose genetically regulated expression in brain tissues is pleiotropic with brain morphology and BMI. Fine-mapping followed by colocalization analysis allows, in several cases, the identification of credible sets of variants likely to be causal for both the macroscopic phenotypes and for gene expression. In particular, epigenetic fine mapping identifies variant rs7187776 in the 5' UTR of the TUFM gene as likely to be causal of increased BMI and decreased caudate volume, possibly through the creation, by the alternate allele, of an ETS binding site leading to increased chromatin accessibility, specifically in microglial cells.

Dietary antioxidants and obesity are considered significant targets for disease prevention in the elderly. However, a possible cardiometabolic multimorbidity (CMM) correlated to dietary antioxidants and obesity is unknown. This study aimed to examine the relationship between dietary antioxidants and obesity with CMM in the older population.

We used data from the NHANES 2003-2018 cycles, including older adults aged 60 and above. Dietary antioxidant status was assessed using the CDAI, calculated from six micronutrients (vitamins A, C, E, selenium, zinc, and carotenoids), and obesity was classified based on BMI. We applied restricted cubic spline models to explore nonlinear associations and logistic regression to assess the associations between pro-oxidant diet, obesity, and CMM. The joint effects of pro-oxidant diet and obesity on CMM were evaluated using additive interaction indices: RERI, AP, and SI, to determine the synergistic impact of these factors. Subgroup analyses by age, sex, ethnicity, and hypertension status were also conducted to assess the synergistic effect of these factors within different population groups.

A total of 13,178 older adults (mean age 69.85 ± 0.10 years; 45.1% male) were included in this study. A pro-oxidant diet and obesity jointly increased CMM risk, with the Pro-oxidant diet & Obese group having the highest risk (adjusted OR 3.11, 95% CI: 2.39-4.04), indicating that their likelihood of CMM was more than three times higher compared to the reference group (Anti-oxidant diet & Non-Obese group). The Anti-oxidant diet & Obese group (adjusted OR 2.03, 95% CI: 1.59-2.59) and the Pro-oxidant diet & Non-Obese group (adjusted OR 1.33, 95% CI: 1.08-1.64) also showed elevated risks, although to a lesser extent. These findings suggest that both dietary factors and obesity independently contribute to CMM risk, but their combined effect is more pronounced. The interaction between a pro-oxidant diet and obesity was synergistic, with the RERI indicating a positive interaction (0.75, 95% CI: 0.21, 1.29), the AP showing 24% of the combined effect due to their interaction, and the SI indicating a synergistic effect greater than additive (SI 1.55, 95% CI: 1.11-2.16). Subgroup analyses showed stronger interactions in females, younger individuals, non-Hispanic Whites, and those with hypertension.

Obesity and a pro-oxidative diet are correlated with the occurrence of CMM; there exists an interaction between obesity and a pro-oxidative diet concerning the initiation and advancement of CMM. Subgroup studies revealed more pronounced interactions among females, younger adults, non-Hispanic Whites, and individuals with hypertension.

Probiotics intervention by Lactobacillus acidophilus has potential effect on alleviating obesity and insulin resistance. However, the limited knowledge of functional substances and potential regulatory mechanisms hinder their widespread application. Herein, L. acidophilus YL01 was firstly isolated from Chinese traditional yogurt, demonstrating inhibitory activities on amylase and glucosidase that are comparable to those of L. rhamnosus LGG. Besides, the oral administration of L. acidophilus YL01 and its EPS significantly reduced body weight in high-fat mice (p < 0.05), as well as fat accumulation in liver and adipocytes. Moreover, they not only reduced fasting blood glucose and glucose/insulin resistance, but also improved dyslipidemia, liver function and inflammation. Further high-performance liquid chromatography analysis and Fourier transform infrared spectroscopy indicated that EPS is an acidic polysaccharide, characterized by a molecular weight of 952 kDa and predominantly composed of glucose. Additionally, the mechanism investigation revealed that the L. acidophilus YL01 and EPS demonstrated limited efficacy in restoring the composition of gut microbiota, but rather exerted an influence on the abundance of specific bacterial groups. The enrichment of the bacterial groups resulted in the increase of acetic acid and butyric acid, which further mediates the gut-liver crosstalk in regulating lipid metabolism by the activation of AMPK/ACC pathway.

The predominant method for treating obesity has been suggesting and providing information on a controlled diet and, to a lesser extent, increased exercise. That approach has largely failed beyond the short term for many decades as obesity rates continue to rise. Therefore, leveraging improvements in psychosocial correlates of weight-loss behaviors has sometimes been suggested instead. The aim of this study was evaluation of targeted improvements in self-regulation and self-efficacy within a theoretically derived weight-loss program. Women with obesity (N = 103) participated in a year-long community-based program emphasizing self-regulatory skills development to counter lifestyle barriers/challenges to first exercise, then controlled eating. Within a structured treatment protocol administered by community facility employees-and based on tenets of social cognitive theory, self-regulation theory, self-efficacy theory, and coaction theory-self-regulatory skills were initially developed to foster adherence to exercise. Those skills were then adapted to promote eating-behavior changes, emphasizing fruit and vegetable intake. Improvements in measures of exercise self-regulation, eating self-regulation, and self-efficacy for controlling eating, their corresponding behaviors, and weight and waist circumference were significant. Greater within-participant carry-over of changes in exercise self-regulation to eating self-regulation was significantly associated with more weight and waist circumference reductions over both 6 and 12 months. Change in eating-related self-efficacy significantly mediated those relationships. The mean weight reduction of approximately 6% indicated positive effects on obesity-related health risks. The community-based setting indicated potentials for large-scale dissemination of theory- and evidence-driven behavioral obesity treatments focused primarily on self-regulatory skills development.

This study aimed to develop a vancomycin population pharmacokinetic model in obese adult patients treated with intermittent haemodialysis and propose a model-based loading dose strategy ensuring attainment of newly recommended AUC-based PK/PD target. Retrospective cross-sectional analysis was performed among obese haemodialysis dependent adult patients treated with intravenous vancomycin. A pharmacokinetic population model was developed using a nonlinear mixed-effects modelling approach and Monte Carlo simulations were used to identify the optimal loading dose for PK/PD target attainment during the first 48 h of treatment. Therapeutic drug monitoring data from 27 patients with a BMI of 30.2-52.9 kg/m2 were analysed. Among all tested variables, only LBM as a covariate of vancomycin Vd significantly improved the model, while vancomycin CL did not correlate with any of the tested variables. The median (IQR) value from the conditional mean of individual estimates of Vd and CL was 68.4 (56.6-84.2) L and 0.86 (0.79-0.90) L/h, respectively. To ensure optimal vancomycin exposure during the first 48 h of therapy, the vancomycin loading dose of 1500, 1750, 2000, 2250, 2500 and 2750 mg should be administered to obese patients with a lean body mass of ˂50, 50-60, 60-70, 70-80, 80-85 and >85 kg, respectively.

This systematic review aimed to determine whether caloric restriction-induced reduction in body fat and fat-free mass can be amended by supplementation with long-chain n-3 polyunsaturated fatty acids. Databases, including PubMed, Google Scholar, Web of Science, and EMBASE, were searched for papers published from the time the databases were created until November 1, 2023. Random-effects model meta-analyses were conducted using Review Manager 5.4.1 software. Statistical heterogeneity was assessed using the I 2. A standardized mean difference with a 95% confidence interval was calculated, and pooled effects were assessed. The initial search identified 1527 articles and 11 studies met the review inclusion criteria with 637 participants included. The participants' ages ranged between 18 and 61 years with a mean body mass index ranging between 27 and 36 kg/m2. The changes in fat-free mass (standardized mean difference = 0.12, 95% CI -0.14 to 0.37, p = 0.36; I 2:35%) and fat mass (standardized mean difference = - 0.01; 95% CI -0.25 to 0.24; p = 0.96; I 2: 46%) were not different between intervention and control groups. The current review indicates that long-chain n-3 polyunsaturated fatty acids supplementation during caloric restriction neither attenuates the decline in fat-free mass nor enhances the reduction in fat mass. Considering the small number of studies and interventions included, further research is needed to investigate the effectiveness of long-chain n-3 polyunsaturated fatty acids supplementation during caloric restriction.

This study examined how different sequences of concurrent training impacted physical activity (PA), body composition, and physical fitness in young obese males. We also investigated whether the effectiveness of these interventions in reducing body fat percentage (BF%) was influenced by PA levels.

A 12-week randomized controlled trial involving a cohort of 45 obese young males (mean age: 22.42 ± 1.96 years, mean BMI: 29.78 ± 3.37) was conducted. Participants were randomly assigned to three groups: the CRE group (Resistance Training (RT) followed by Endurance Training (ET)), the CER group (ET followed by RT), and the control group (Con). The training sessions were held three times a week. Measurements, including PA level, body composition, bone density, VO2max, and muscle strength, were assessed before and after the intervention.

Compared to those at baseline, following the intervention, both the CRE and CER groups showed significant improvements in various parameters, including PA level, body composition, bone density, VO2max, and muscle strength (p < 0.05), whereas no significant changes were observed in the Con group (p > 0.05). Specifically, the CRE group demonstrated remarkable progress, as evidenced by an increase in MVPA level (η2 p = 0.37, p < 0.001), a reduction in fat mass (η2 p = 0.28, p < 0.001), BF% (η2 p = 0.28, p < 0.001), android fat (%) (η2 p = 0.21, p < 0.001), gynoid fat (%) (η2 p = 0.30, p < 0.001), and various physical fitness indices, such as maximum strength (η2 p = 0.20, p = 0.008), explosive strength (η2 p = 0.38, p < 0.001), and muscular endurance (η2 p = 0.55, p < 0.001), surpassing the improvements observed in the CER and Con groups. Changes in PA levels during the intervention influence the efficacy of CT in reducing BF%.

CT, particularly when RT precedes ET, had the potential to improve PA levels, overall physical fitness, body composition, and bone health in obese young males. Moreover, changes in PA levels during the intervention impacted the effectiveness of CT in reducing BF%.

ChiCTR, ChiCTR2200063892.

Low-carbohydrate diets and intermittent energy restriction may offer metabolic advantages in fuel utilisation, that are independent of weight loss. The underlying mechanisms for these effects are unclear but may involve extensions of the catabolic phase and/or attenuation of insulin secretion. To address this gap, we aimed to investigate the independent acute metabolic effect of carbohydrate restriction at varying energy levels. Twelve, (six female) healthy overweight/obese participants (27.3 ± 1.8 years; 25.2 ± 1.6 kg/m2) completed this three-way study. Volunteers followed three diets for one day (36 h, covering the intervention day and overnight fasting), separated by 5-day washout: a normal carbohydrate, energy-balanced diet (nEB, 55% CHO), a low-carbohydrate, energy-balanced diet (LCEB, 50 g/day CHO), and a low-carbohydrate, energy-restricted diet (LC25, 50 g/day CHO with 75% energy restriction). Fasting and serial postprandial (360 min) measurements to a mixed test meal were collected the following morning. Additionally, subjective appetite responses and two-day subsequent ad libitum food intake was assessed. Both low-carbohydrate with and without energy restriction diets induced comparable decrease in triacylglycerol iAUC (p = 0.02, p = 0.04, respectively), and respiratory quotient (both p < 0.01) along with increase in non-esterified fatty acids (both p < 0.01) and 3-hydroxybutyrate (p = 0.001, p = 0.01, respectively) levels. Compared to a non-restricted carbohydrate, energy-balanced diet, postprandial glucose levels significantly increased in the LCEB arm (p = 0.024) and showed a rising trend in the LC25 arm (p = 0.07). Neither insulin responses nor resting, and diet-induced thermogenesis were significantly altered by variations in energy or carbohydrate content. These findings demonstrate that carbohydrate restriction, without altering energy intake, can elicit effects similar to those observed in short-term fasting. As such we propose a strategy of repeated carbohydrate restriction cycles alone may be an emerging alternative approach for the enhancement of cardiometabolic health, warranting further investigation.

Obesity arises from an imbalance between adipogenesis and adipocyte thermogenesis. Interleukin-27 (IL-27), a heterodimer cytokine, is known to promote thermogenesis in brown adipose tissue. However, its role in adipogenesis remains unclear. This study aims to investigate the effects of IL-27 on adipogenesis both in vitro and in vivo, and to elucidate the underlying mechanisms. In vitro, an adipogenic differentiation model of adipose-derived mesenchymal stem cells (ADSCs) demonstrate that IL-27 is non-cytotoxic to ADSCs and inhibits ADSCs adipogenic differentiation. In vivo, using a high-fat diet (HFD)-induced obese mouse model and a targeted adipose tissue-specific IL-27 overexpression adeno-associated viral (AAV) vector, we confirm that IL-27 suppresses adipogenesis, prevents weight gain, and improves glucose and lipid metabolic homeostasis in obese mice. Additionally, the inhibition of adipogenesis by IL-27 is mediated through HDAC6 activation of the TGFβ/Smad3 signaling pathway. Our study suggests that IL-27 is a potential therapeutic target for obesity and metabolic disorders.

Obesity is projected to affect nearly 42% of Americans nationwide by 2050. Waist circumference (WC), an estimate of central obesity or adiposity, has been shown to be a better predictor for cardiometabolic morbidity and mortality than body mass index (BMI), which does not consider body fat distribution. This study aimed to evaluate whether: 1) WC correlates with increasing BMI cohorts; and 2) WC is a predictor of severe Clavien-Dindo IV complications within 30 days following total knee arthroplasty (TKA).

A national dataset was retrospectively queried to identify patients who received primary TKA for knee osteoarthritis between 2010 and 2020 (N = 385,996). A validated model converted each patient's BMI to WC. The BMI cohorts were grouped into underweight, healthy weight, overweight, and obesity classes 1 to 3. Primary outcomes included comparing WC among different BMI cohorts undergoing TKA. The secondary outcome was to evaluate if WC was associated with severe surgical complications within 30 days. Clavien-Dindo IV complications included cardiac arrests, myocardial infarctions, septic shock episodes, pulmonary emboli, acute renal failures, and cerebrovascular accidents. Multivariable logistic regressions were adjusted for age, functional status, frailty, various comorbidities, and obesity to evaluate the odds ratios (ORs) between WC and postoperative complications following TKA, with P-values less than 0.001 as significant.

The mean WC significantly correlated with increasing BMI cohorts (P < 0.001). The mean WC was significantly higher among patients who developed Clavien-Dindo IV complications (112.4 versus 110.5 centimeters, P < 0.001). For all TKA patients, each centimeter increase in WC was associated with developing a postoperative complication (OR: 1.11, P < 0.001). Subanalysis of only obese patients showed WC to be a better predictor than BMI class (OR: 1.35, P < 0.001).

Central adiposity, measured by WC, was associated with severe complications following TKA, even when controlling for obesity. Screening interventions using waist measurements may assist joint arthroplasty surgeons in risk-stratifying patients who have higher BMIs. Further study is warranted on how to integrate WC into TKA practice.

Obesity and overweight are increasingly recognized as significant risk factors for the incidence and progression of thyroid cancer (TC). However, its epidemiological investigation including the disease burden and its trends remains insufficiently explored. This research aimed to reveal and predict the disease burden of thyroid cancer attributable to high body-mass index (TC-HBMI), which would offer significant references for focused prevention and disease management methods.

The study extracted data from the Global Burden of Disease Study 2021 (GBD 2021). Deaths case, disability-adjusted life years (DALYs) case, age-standardized mortality rate (ASMR) and age-standardized DALYs rate (ASDR) were obtained from GBD 2021 to assess the global burden from 1990 to 2021. Decomposition analysis explored the driving factors to TC-HBMI. The Average Annual Percent Change (AAPC) in ASMR and ASDR of TC-HBMI was determined to analyze temporal trends by Joinpoint regression analysis. Bayesian age-period-cohort (BAPC) model was utilized to project the disease burden untill 2049.

The global deaths and DALYs of TC-HBMI were 5,255 and 144,955 in 2021, exhibiting a continuous growth trend over the past 32 years. The ASMR and ASDR for males showed faster growth. The disease burden was greatest among middle-aged and older populations, while the rapidly increase in adolescents should not be overlooked. High socio-demographic index (SDI) regions and Latin America each recorded the highest disease burden within their respective categories of SDI regions and GBD regions. Additionally, Predictive models indicated a gradual upward trend from 2022 to 2049.

The study revealed that the global disease burden of TC-HBMI had continuously increased from 1990 to 2021, and it was predicted to escalate until 2049. The findings emphasize the need for more detailed TC screening and weight loss measures tailored to specific regions and populations, which would benefit efforts to curb the projected rise in TC-HBMI deaths and DALYs.

As the global population ages, obesity among older adults has become an increasing public health concern. Lifestyle factors, including physical activity (PA) and sleep, play a critical role in obesity prevention. These behaviors occur within a 24-hour cycle, yet research on the impact of different PA patterns, trouble sleeping, and their combination on obesity in older adults remains limited. This study aimed to explore: (1) the relationship between PA patterns, trouble sleeping, and obesity among older Americans; and (2) the combined effect of PA patterns and trouble sleeping on obesity in this population.

A total of 10,891 participants aged 60 and older (55.0% female) from the National Health and Nutrition Examination Survey 2007-2018 were included. Trouble sleeping was assessed using the Sleep Disorder Questionnaire, and PA was measured using the Global Physical Activity Questionnaire. Body mass index (BMI) was calculated from objectively measured weight and height. Multivariate linear regression models were used to estimate the association between PA patterns, trouble sleeping, and BMI.

Compared to the inactive group, participants in the insufficiently active group (β = -0.75; 95% CI = -1.27 to -0.23; P = 0.005), weekend warrior group (β = -1.08; 95% CI = -1.88 to -0.28; P = 0.009), and regularly active group (β = -1.58; 95% CI = -2.02 to -1.14; P < 0.001) had a significant negative association with BMI. Participants with trouble sleeping exhibited a positive association with BMI compared to those without trouble sleeping (β = 0.39; 95% CI = 0.02 to 0.75; P = 0.040). Conversely, among participants with trouble sleeping, those who were regularly active exhibited a negative association with BMI (β = -0.56; 95% CI = -1.05 to -0.07; P = 0.027). Additionally, compared to sufficiently active group, both the inactive and insufficiently active groups exhibited a positive association with BMI, regardless of the presence of trouble sleeping.

Insufficient PA and trouble sleeping in older adults are positively associated with obesity. Engaging in either a weekend warrior or regular PA lifestyle is negatively associated with obesity. Furthermore, adopting a regularly active lifestyle may mitigate the negative impact of trouble sleeping on obesity. However, regardless of the presence of trouble sleeping, insufficient PA remains positively associated with obesity in older adults.

Overweight and obesity is a global epidemic. Forecasting future trajectories of the epidemic is crucial for providing an evidence base for policy change. In this study, we examine the historical trends of the global, regional, and national prevalence of adult overweight and obesity from 1990 to 2021 and forecast the future trajectories to 2050.

Leveraging established methodology from the Global Burden of Diseases, Injuries, and Risk Factors Study, we estimated the prevalence of overweight and obesity among individuals aged 25 years and older by age and sex for 204 countries and territories from 1990 to 2050. Retrospective and current prevalence trends were derived based on both self-reported and measured anthropometric data extracted from 1350 unique sources, which include survey microdata and reports, as well as published literature. Specific adjustment was applied to correct for self-report bias. Spatiotemporal Gaussian process regression models were used to synthesise data, leveraging both spatial and temporal correlation in epidemiological trends, to optimise the comparability of results across time and geographies. To generate forecast estimates, we used forecasts of the Socio-demographic Index and temporal correlation patterns presented as annualised rate of change to inform future trajectories. We considered a reference scenario assuming the continuation of historical trends.

Rates of overweight and obesity increased at the global and regional levels, and in all nations, between 1990 and 2021. In 2021, an estimated 1·00 billion (95% uncertainty interval [UI] 0·989-1·01) adult males and 1·11 billion (1·10-1·12) adult females had overweight and obesity. China had the largest population of adults with overweight and obesity (402 million [397-407] individuals), followed by India (180 million [167-194]) and the USA (172 million [169-174]). The highest age-standardised prevalence of overweight and obesity was observed in countries in Oceania and north Africa and the Middle East, with many of these countries reporting prevalence of more than 80% in adults. Compared with 1990, the global prevalence of obesity had increased by 155·1% (149·8-160·3) in males and 104·9% (95% UI 100·9-108·8) in females. The most rapid rise in obesity prevalence was observed in the north Africa and the Middle East super-region, where age-standardised prevalence rates in males more than tripled and in females more than doubled. Assuming the continuation of historical trends, by 2050, we forecast that the total number of adults living with overweight and obesity will reach 3·80 billion (95% UI 3·39-4·04), over half of the likely global adult population at that time. While China, India, and the USA will continue to constitute a large proportion of the global population with overweight and obesity, the number in the sub-Saharan Africa super-region is forecasted to increase by 254·8% (234·4-269·5). In Nigeria specifically, the number of adults with overweight and obesity is forecasted to rise to 141 million (121-162) by 2050, making it the country with the fourth-largest population with overweight and obesity.

No country to date has successfully curbed the rising rates of adult overweight and obesity. Without immediate and effective intervention, overweight and obesity will continue to increase globally. Particularly in Asia and Africa, driven by growing populations, the number of individuals with overweight and obesity is forecast to rise substantially. These regions will face a considerable increase in obesity-related disease burden. Merely acknowledging obesity as a global health issue would be negligent on the part of global health and public health practitioners; more aggressive and targeted measures are required to address this crisis, as obesity is one of the foremost avertible risks to health now and in the future and poses an unparalleled threat of premature disease and death at local, national, and global levels.

Bill & Melinda Gates Foundation.

Diverse analysis has analyzed the potential efficacy of consuming foods created through the fermentation of dairy in mitigating abdominal obesity. The current meta-analysis aims to determine the impacts of consuming fermented dairy foods and the occurrence of abdominal obesity.

Web of Science, PubMed, and Scopus databases were queried for records published before January 13, 2023, to investigate proportionate cohort studies. We employed a random-effects model to appraise the relative risk (RR); effect size was assessed through the 95% confidence interval (CI). Additionally, a one-stage dose-response analysis was executed, quality assessment was conducted through the ROBINS-E tool.

Consequently, five publications, comprising 41,430 cases, were included as selected studies. The pooled effect shows an effect on the abdominal obesity risk; however, the effect was not significant. Subgroup analyses revealed a potential risk reduction effect in high- and low-fat and fermented dairy productions, although the findings were not statistically significant. Furthermore, the dose-response analysis indicated a linear decrease in risk with increasing consumption of high-fat fermented yogurt, with an HR of 0.84 (95% CI 0.71, 0.99) by 8 servings/week and an HR of 0.37 (95% CI 0.19, 0.71) by 21 servings/week.

These findings imply the potential effectiveness of fermented dairy products, particularly high-fat yogurt, in diminishing the obesity risk. However, further research addressing the limitations of previous studies is essential to confirm these results. Evidence-based medicine level: No level of evidence: Level of evidence III. PROSPERO registration number: CRD42023387538 ( http://www.crd.york.ac.uk/PROSPERO ).

Emerging data on cardiovascular outcomes, specifically major adverse cardiovascular events (MACE), are being reported from various trials involving incretin mimetics, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) and glucose-dependent insulinotropic polypeptide (GIP), especially among patients with obesity and diabetes. Our aim was to evaluate this matter, while also involving various traditional cardiovascular risk factors [e.g., several body weight (BW) parameters, blood pressure (BP), lipid profile].

A search of PubMed, Europe PMC, ScienceDirect, Cochrane, and ClinicalTrials.gov up to September 2024 was performed to identify GLP-1 RA and GIP trials in MACE risk reduction as a primary endpoint. Our secondary endpoints included a reduction in BW, waist circumference (WC), body mass index (BMI), BP changes, and lipid modifying effects, while also yielding safety concerns surrounding the use of these pharmaceutical agents. Mean differences (MD) and risk ratios (RR) were summarized using random-effects model.

A total of 11 eligible randomized controlled trials (RCTs) comprising 8 GLP-1 RA trials and 3 dual GLP-1 RA/GIP (tirzepatide) trials were included. Compared with control groups, GLP-1 RA significantly reduced the MACE risk by 32% [RR 0.68 (95% CI 0.53-0.87); P = 0.002; I2 = 73%, P-heterogeneity < 0.001] and 59% for tirzepatide [RR 0.41 (95% CI 0.18-0.92); P = 0.03; I2 = 0%, P-heterogeneity = 0.96]. Incretin mimetics also substantially reduced BW, BP, and improved lipid panel measures. However, there was an increased risk of adverse events, specifically gastrointestinal disorders within the incretin mimetics subset.

Incretin mimetics have shown promise in reducing MACE risk while also enhancing cardiovascular risk factors, including blood pressure and lipid profile, in adults with obesity without diabetes.

Non-communicable diseases (NCDs), such as type 2 diabetes (T2D) and metabolic dysfunction-associated fatty liver disease, have reached epidemic proportions worldwide. The global increase in dietary sugar consumption, which is largely attributed to the production and widespread use of cheap alternatives such as high-fructose corn syrup, is a major driving factor of NCDs. Therefore, a comprehensive understanding of sugar metabolism and its impact on host health is imperative to rise to the challenge of reducing NCDs. Notably, fructose appears to exert more pronounced deleterious effects than glucose, as hepatic fructose metabolism induces de novo lipogenesis and insulin resistance through distinct mechanisms. Furthermore, recent studies have demonstrated an intricate relationship between sugar metabolism and the small intestinal microbiota (SIM). In contrast to the beneficial role of colonic microbiota in complex carbohydrate metabolism, sugar metabolism by the SIM appears to be less beneficial to the host as it can generate toxic metabolites. These fermentation products can serve as a substrate for fatty acid synthesis, imposing negative health effects on the host. Nevertheless, due to the challenging accessibility of the small intestine, our knowledge of the SIM and its involvement in sugar metabolism remains limited. This review presents an overview of the current knowledge in this field along with implications for future research, ultimately offering potential therapeutic avenues for addressing NCDs.

Obesity-induced bone loss affects the life quality of patients all over the world. Irisin, one of the myokines, plays an essential role in bone and fat metabolism.

Investigate the effects of irisin on bone metabolism via adipocytes in the bone marrow microenvironment.

In this study, we fed fibronectin type III domain-containing protein 5 (FNDC5, the precursor protein of irisin) knockout mice (FNDC5-/-) with a high-fat diet (HFD) for 10 weeks. The quality of bone mass was assessed by micro-CT analysis, histological staining, and dynamic bone formation. In vitro, the lipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) was assayed by Oil Red O staining, and the osteogenic differentiation was assayed by alkaline phosphatase staining. Meanwhile, the gene expression in the BMSC-differentiated adipocytes by RNA sequence and the involved pathway of irisin were determined by western blot and qRT-PCR were performed.

The FNDC5-/- mice fed with a HFD showed an increased body weight, fat content of the bone marrow and bone, and a decreased bone formation compared with those with a standard diet (SD). In vitro, irisin inhibited the differentiation of BMSCs into adipocytes and alleviated the inhibition of osteogenesis derived from BMSCs by the adipocyte supernatant. RNA sequence and blocking experiment showed that irisin reduced the production of interleukin 6 (IL-6) in adipocytes through downregulating the TLR4/MyD88/NF-κB pathway. Immunofluorescence staining of bone marrow further confirmed an increased IL-6 expression in the FNDC5-/- mice fed with HFD compared with those fed with SD, which suffered serious bone loss.

Irisin downregulates activation of the TLR4/MyD88/NF-κB pathway, thereby reducing IL-6 production in adipocytes to enhance the osteogenesis of BMSCs. Thus, the rescue of osteogenesis of BMSCs, initially inhibited by IL-6, is a potential therapeutic target to mitigate obesity-induced osteoporosis.

The relationship between body mass index (BMI) and clinical outcomes in patients with cardiovascular disease, including acute heart failure (AHF) and acute myocardial infarction (AMI), remains debated. This study investigates the association between BMI and clinical outcomes within the PARADISE-MI cohort, while also evaluating the impact of angiotensin receptor-neprilysin inhibitor (ARNI) versus angiotensin-converting enzyme inhibitor (ACE-I) treatment on this relationship.

The analysis included 5589 patients from the PARADISE-MI study with available baseline BMI data. The cohort comprised patients with AMI and pulmonary congestion and/or left ventricular ejection fraction ≤40%. Patients were categorized into six World Health Organization BMI subgroups. The primary outcome of interest was the composite endpoint of cardiovascular death, heart failure (HF)-associated hospitalization, and outpatient symptomatic HF episodes. The mean baseline BMI of the cohort was 28.1 ± 5.0 kg/m2. The lowest rate of the primary composite endpoint (6.2/100 patient-years) was observed in overweight patients (BMI 25-29.9 kg/m2), while the highest rates were found in the lowest and highest BMI subgroups (8.4/100 patient-years for BMI <18.5 kg/m2 and 9.7/100 patient-years for BMI >40 kg/m2). There was no significant interaction between BMI and the treatment effect of ARNI versus ACE-I on the primary composite outcome (p = 0.73). Additionally, no significant differences in the incidence of adverse events or serious adverse events were noted across the BMI subgroups.

In AMI with AHF patients, the relationship between BMI and the primary composite outcome is non-linear, with the lowest event rates observed in overweight individuals. Outcomes and safety profiles for ARNI and ACE-I treatments were similar across BMI subgroups.

Obesity and the metabolic syndrome (MetS) are major global health challenges that contribute significantly to the rising prevalence of type 2 diabetes (T2D) and neuropathy. Neuropathy, a common and disabling complication of T2D, is characterized by progressive distal-to-proximal axonal degeneration, driven in part by mitochondrial dysfunction in both neurons and axons. Recent evidence points to the toxic effects of saturated fatty acids on peripheral nerve health, with studies demonstrating that these fats impair mitochondrial function and bioenergetics, leading to distal axonal loss. Conversely, monounsaturated fatty acids are found to be neuroprotective, restoring mitochondrial function and preventing neuropathy. These findings suggest that dietary factors play a crucial role in the pathogenesis of neuropathy associated with metabolic dysregulation and emphasize the need for lifestyle interventions and therapies that target these newly identified mechanisms.

The prevalence of type 2 diabetes (T2D) and obesity are increasing in the United States. However, population-level data for mortality trends due to T2D and obesity are limited. This study aims to assess these death trends among adults in the United States categorized by sex, race, and geographical location.

We queried the CDC-WONDER database for multiple cause of death data of adults aged ≥25 years. The crude mortality rates (CMR), age-adjusted mortality rates (AAMRs), annual percent change (APC), and the average APC (AAPC) along with a 95% confidence interval (CI) were analyzed.

From 1999 to 2022, a total of 88,597 T2DM and obesity-related deaths were recorded in the United States. The AAMR consistently increased from 1999 to 2017 (APC: 7.64; 95% CI: 1.91-9.96), followed by a marked rise from 2017 to 2022 (APC: 20.13; 95% CI: 12.88-38.57). The AAMR was approximately 3.58 times higher during the COVID-19 pandemic compared to the period from 1999 to 2019. The AAMR for males was consistently greater than that for females. The highest AAMR was observed in non-Hispanic (NH) Blacks or African Americans, followed by NH White, Hispanic or Latino, and other NH populations. Rural areas (AAMR: 1.86, 95% CI: 1.83-1.89) exhibited a greater AAMR than urban regions 1.26 (95% CI: 1.25-1.27).

Our results indicate a substantial increasing trend of T2D and obesity-related deaths in the United States especially during the COVID-19 pandemic.

Background The relationship between body mass index (BMI) and the risk of sick sinus syndrome (SSS) remains unclear. Clarifying the impact of BMI on SSS at different life stages is essential for advancing precision medicine and implementing effective prevention strategies to reduce the burden of SSS. Methods The causalities of childhood and adult BMI with SSS were investigated by univariate and multivariate Mendelian randomization. Reverse causalities were also explored to improve the accuracy of causality findings. Different sources of exposure data were used for replication analysis, and the effects of sample overlap were investigated using MRlap. The stability of the results was further enhanced through meta-analysis. Results There was a positive correlation of adult BMI with the risk of SSS in both the FinnGen (odds ratio (OR) = 1.17, 95% confidence interval (CI) 1.01-1.35, P = 0.031) and Integrative Epidemiology Unit (IEU) open genome-wide association study (GWAS) project (OR = 1.18, 95% CI 1.04-1.34, P = 0.009) databases. The causality remained valid after the correction of telomere length. There was no causality detected between childhood BMI and SSS, as determined by independent studies of the Early Growth Genetics (EGG) 2020 (OR = 1.06, 95% CI 0.89-1.27, P = 0.513) and EGG2015 (OR = 1.02, 95% CI 0.97-1.09, P = 0.423). Meta-analysis results further confirmed the reliability of the causal inference. Conclusions The findings indicate that elevated BMI in adults, particularly among middle-aged and elderly populations, increases the risk of developing SSS. In contrast, no causal relationship was observed between childhood BMI and SSS, suggesting that the influence of BMI on SSS susceptibility may predominantly emerge during later life stages. These results highlight the need for targeted public health interventions to address adult obesity as a modifiable risk factor for SSS.

Over the past 50 years, the incidence of obesity has gradually increased, necessitating investigation into the multifactorial contributors to this disease, including the gut microbiota. Bacteria within the human gut microbiome communicate using a density-dependent process known as quorum sensing (QS), in which autoinducer (AI) molecules (e.g., N-acyl-homoserine lactones [AHLs]) are produced to enable bacterial interactions and regulate gene expression.

We aimed to disrupt QS using quorum quenching (QQ) lactonases GcL and SsoPox, which cleave AHL signaling molecules in a taxa-specific manner based on differing enzyme affinities for different substrates. We hypothesized that QQ hinders signals from obesity-associated pathobionts, thereby slowing or preventing obesity.

In a murine model of diet-induced obesity, we observed GcL and SsoPox treatments have separate sex-dependent and dose-dependent effects on intestinal community composition and diversity. Notably, male mice given 2 mg/mL SsoPox exhibited significant changes in the relative abundances of gram-negative taxa, including Porphyromonadaceae, Akkermansiaceae, Muribaculaceae, and Bacteroidales (Kruskal-Wallis p < 0.001). Additionally, we used covariance matrix network analysis to model bacterial taxa co-occurrence due to QQ enzyme administration. There were more associations among taxa in control mice, particularly among gram-negative bacteria, whereas mice receiving SsoPox had the fewest associations.

Overall, our study establishes proof of concept that QQ is a targetable strategy for microbial control in vivo. Further characterization and dosage optimization of QQ enzymes are necessary to harness their therapeutic capability for the treatment of chronic microbial-associated diseases.

Greater than 650 million individuals worldwide are categorized as obese, which is associated with significant health, economic, and social challenges. Given its overlap with leading comorbidities such as heart disease, innovative solutions are necessary to improve risk prediction and management strategies. In recent years, artificial intelligence (AI) and machine learning (ML) have emerged as powerful tools in healthcare, offering novel approaches to chronic disease prevention. This narrative review explores the role of AI/ML in obesity risk prediction and management, with a special focus on childhood obesity. We begin by examining the multifactorial nature of obesity, including genetic, behavioral, and environmental factors, and the limitations of traditional approaches to predict and treat morbidity associated obesity. Next, we analyze AI/ML techniques commonly used to predict obesity risk, particularly in minimizing childhood obesity risk. We shift to the application of AI/ML in obesity management, comparing perspectives from healthcare providers versus patients. From the provider's perspective, AI/ML tools offer real-time data from electronic medical records, wearables, and health apps to stratify patient risk, customize treatment plans, and enhance clinical decision making. From the patient's perspective, AI/ML-driven interventions offer personalized coaching and improve long-term engagement in health management. Finally, we address key limitations and challenges, such as the role of social determinants of health, in embracing the role of AI/ML in obesity management, while offering our recommendations based on our literature review.

Obesity is strongly associated with cardiometabolic disorders and certain malignancies, emphasizing the key role of adipose tissue in human health. While incretin mimetics have shown effectiveness in glycemic control and weight loss, a holistic strategy for combating obesity and associated comorbidities remains elusive. This review explores peroxisome proliferator-activated receptor gamma (PPAR-γ) agonism as a potential therapeutic approach, highlighting its benefits, addressing its limitations, and outlining future directions for developing more effective treatment strategies.

Both natural and synthetic PPAR-γ agonists hold significant therapeutic potential as insulin sensitizers, while also demonstrating anti-inflammatory properties and playing a critical role in regulating lipid metabolism. However, the clinical use of natural agonists is limited by poor bioavailability, while synthetic agents like thiazolidinediones are associated with adverse effects, including fluid retention, weight gain, and bone loss. Current research is focused on developing modified, tissue-specific PPAR-γ agonists, as well as dual PPAR-α/PPAR-γ agonists, with improved safety profiles to mitigate these side effects. Nanotechnology-based drug delivery systems also hold promise for enhancing bioavailability and therapeutic efficacy. Furthermore, the transformative potential of machine learning and artificial intelligence offers opportunities to accelerate advancements in this field. PPAR-γ agonists exhibit significant potential in addressing metabolic syndrome, cardiovascular disease, and cancer. However, their clinical use is restricted by safety concerns and suboptimal pharmacokinetics. Innovations in modified PPAR-γ agonists, nanotechnology-based delivery systems, and computational tools hold promise for creating safer and more effective therapeutic options for obesity and its associated disorders.

To explore the genetic links between obesity, glycemic traits and retinal vein occlusion (RVO).

Summary-level statistics for obesity and glycemic traits were extracted from publicly available genome-wide association studies (GWAS) of European participants in the IEU Open GWAS database. Genetic associations with clinically diagnosed RVO were obtained from the FinnGenresearch project (372 cases and 182,573 controls). Two-sample Mendelian randomization (MR) and multivariate MR (MVMR) analysis were performed to determine the total effect and direct effect, respectively.

After adjustment for the false discovery rate (FDR), the primary inverse-variance-weighted (IVW) methods indicated that the odds ratios of RVO increased with per 1-standard deviation increased in body mass index (BMI) (OR = 1.94, 95% CI: 1.23-3.08,p-FDR = 0.025), waist circumference (OR = 2.4, 95% CI: 1.36-4.24, p-FDR = 0.019), fasting glucose (OR = 5.01, 95% CI: 2-12.55, p-FDR = 0.0067) and two-hour glucose (OR = 3.17, 95% CI: 1.63-6.18,p-FDR = 0.0067). Higher whole-body fat-free mass (OR = 0.45, 95% CI: 0.26-0.8,p-FDR = 0.025) is a potential protective factor for RVO. In addition, the results of MVMR showed that BMI, whole-body fat-free mass, fasting glucose and two-hour glucose were independent factors that had a direct impact on the onset of RVO.

Our comprehensive MR analysis suggested significant genetic associations between BMI, whole-body fat-free mass, fasting glucose, two-hour glucose and RVO. This study highlighted the importance of weight, blood glucose management and physical activity for primary prevention and control of RVO.

Purpose: This review aims to explore the clinical and research applications of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), in understanding, predicting, and managing obesity. It assesses the use of AI tools to identify obesity-related risk factors, predict outcomes, personalize treatments, and improve healthcare interventions for obesity. Methods: A comprehensive literature search was conducted using PubMed and Google Scholar, with keywords including "artificial intelligence", "machine learning", "deep learning", "obesity", "obesity management", and related terms. Studies focusing on AI's role in obesity research, management, and therapeutic interventions were reviewed, including observational studies, systematic reviews, and clinical applications. Results: This review identifies numerous AI-driven models, such as ML and DL, used in obesity prediction, patient stratification, and personalized management strategies. Applications of AI in obesity research include risk prediction, early detection, and individualization of treatment plans. AI has facilitated the development of predictive models utilizing various data sources, such as genetic, epigenetic, and clinical data. However, AI models vary in effectiveness, influenced by dataset type, research goals, and model interpretability. Performance metrics such as accuracy, precision, recall, and F1-score were evaluated to optimize model selection. Conclusions: AI offers promising advancements in obesity management, enabling more personalized and efficient care. While technology presents considerable potential, challenges such as data quality, ethical considerations, and technical requirements remain. Addressing these will be essential to fully harness AI's potential in obesity research and treatment, supporting a shift toward precision healthcare.

This study aimed to examine the associations between substituting sedentary time (ST) with physical activity and sleep with obesity parameters in adults from eight Latin American countries. The sample consisted of 2173 adults aged 18-65 years. Physical activity, ST and sleep were objectively measured using accelerometers. The parameters of obesity were defined using body mass index (BMI) and waist circumference (WC). Regression analyses were conducted for isotemporal analysis of the association between substituting 30 min/day of ST with light physical activity (LPA), moderate to vigorous physical activity (MVPA) and sleep in relation to BMI and WC. Substituting light physical activity with higher intensity was also analyzed. Substituting 30 min/day of ST with MVPA was significantly associated with lower odds of a higher BMI (OR: 0.993, 95%CI 0.990-0.998) and WC (OR: 0.998, 95%CI 0.998-0.999). Conversely, substituting ST with LPA did not show a significant impact on obesity parameters. However, the substitution of 30 min/day of LPA with MVPA was also associated with lower odds of a higher BMI (OR: 0.993, 95%CI 0.989-0.997). The results highlight the importance of replacing ST and increasing the intensity of physical activity as an effective strategy for preventing and managing obesity in Latin America.

Obesity is a major global health concern, with diet playing a crucial role in its development and treatment. Ultra-processed foods (UPFs) have become prevalent in diets due to changes in the food environment. These foods are energy-dense; high in fat, sugars, or salt; and low in fiber, protein, vitamins, and minerals, raising concerns about their effects on health. In addition to traditional research focused on nutrients, food, and dietary quality, growing evidence has linked UPF consumption to obesity. Therefore, this study provides a comprehensive review of the levels and trends of UPF consumption, current epidemiological evidence on the association between UPF consumption and obesity, and UPFs' potential role in the etiology of obesity and weight gain. Additionally, this study reviews strategies for reducing UPF consumption and outlines future studies of the link between UPF consumption and obesity.

Recurrent spontaneous abortion (RSA), characterized by the loss of two or more pregnancies, impacts approximately 1-2% of couples and poses a significant challenge for individuals of childbearing age. The precise mechanisms underlying RSA remain incompletely understood. Concurrently, the global prevalence of obesity is on the rise, with obesity being closely associated with female reproductive disorders and infertility. This study initially examines the pathways through which obesity contributes to RSA, encompassing factors such as embryonic euploid miscarriage, endometrial development, immune function, among others. Furthermore, adipokines and the fat mass and obesity-related (FTO) are identified as potential contributors to RSA. The study also explores the enhancement of pregnancy outcomes through various weight management strategies, with a particular focus on the roles of dietary interventions, physical activity, and weight control during pregnancy. Obesity is closely related to RSA in multiple aspects. Additional clinical prospective and experimental studies are required to explore its precise pathogenesis. Through this review, we aim to provide strategies for improvement and treatment approaches for RSA related to obesity. Through this review, we suggest potential clinical management strategies and research avenues aimed at offering enhancements and therapeutic insights for miscarriages linked to obesity and its associated risk factors.

Identifying past, present, and future temporal trends in gallbladder and biliary tract cancer (GBTC) can increase public awareness and promote changes in prevention and treatment strategies.

The incidence and death rates of GBTC between 1990 and 2021 were extracted from the Global Burden of Disease study 2021 and assessed according to country, region, year, age, and sex. Time trends were measured using the average annual percentage change (AAPC) and projections of the burden of disease for 2022 to 2045 were made using the Bayesian age-period-cohort model.

In 2021, there were 216,768.3 new cases (95% uncertainty interval [UI], 181,888.0-245,237.6) and 171,961.2 deaths (95% UI, 142,351.8-194,238.4) in GBTC globally. The increases in incidence and deaths were 101.09% and 74.26%, respectively, compared with 1990. The GBTC burden was higher in females and older adults. However, age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) trended downward from 1990 to 2021, with AAPC at -0.39 (95% CI, -0.52 to -0.26) and -0.88 (95% CI, -0.96 to -0.79), respectively. Although the ASIR and ASDR for both sexes are projected to decline gradually from 2022 to 2045, the incidence and deaths are expected to increase steadily. In addition, the global proportion of GBTC deaths owing to high body mass index in 2021 was 12.66% for females and 10.48% for males, which did not change significantly from 1990.

GBTC is becoming a major global health burden, especially among females and older adults. Given the increasing burden of an aging population, there is a need to reduce the incidence of this disease by adopting effective strategies and measures targeting risk factors.

Obesity is a serious public health challenge worldwide, the present study is aimed to investigate the structural characteristic and anti-obesity effect of a water-soluble galactomannan (PEC) extracted from Eurotium cristatum (E. cristatum). Detailed analysis of the PEC structure showed a weight-average molecular weight of 32,305 Da and a composition of mainly mannose, galactose and small amounts of glucose. Nuclear magnetic resonance spectroscopy combined with methylation analysis indicated that the main chain of PEC is →5)-β-D-Galf-(1 → 6)-α-D-Manp-(1 → glycosidic bond, and the branched chain →2)-α-D-Manp-(1 → through →2,6)-α-D-Manp-(1 → is connected to the main chain by an O-2 bond. Furthermore, PEC was found to ameliorate body weight gain, metabolic disorders, and to modulate the gut microbiota in HFD-fed mice. Fecal microbiota transplantation trial confirmed that PEC prevented obesity development and metabolic disorders by reversing gut dysbiosis in HFD-fed mice. This is the first report of the isolation of PEC from E. cristatum, and the findings suggested that PEC exerted its antiobesity and related beneficial effects by regulating the gut microbiota. In conclusion, as a polysaccharide, PEC could reduce obesity by modulating the gut microbiota and has potential been a prophylactic agent for obesity and related metabolic diseases.

Obesity has emerged as a global epidemic with far-reaching health complications, including its role as an independent risk factor for chronic kidney disease (CKD). Increasing evidence suggests that obesity contributes to CKD through multiple mechanisms, including chronic inflammation, hemodynamic alterations, insulin resistance, and lipid accumulation. These processes can culminate in histopathological changes collectively referred to as obesity-related glomerulopathy (ORG). This review aims to provide a comprehensive overview of the current knowledge regarding the prevalence, clinical manifestations, and pathophysiology of ORG. Furthermore, we emphasize the importance of identifying key biomarkers that facilitate the early detection of ORG. Finally, we explore emerging therapeutic strategies that offer promise in mitigating this growing global health crisis.

Obesity is a multifactorial disease reaching pandemic proportions with increasing healthcare costs, advocating the development of better prevention and treatment strategies. Previous research indicates that the gut microbiome plays an important role in metabolic, hormonal, and neuronal cross-talk underlying eating behavior. We therefore aim to examine the effects of prebiotic and neurocognitive behavioral interventions on food decision-making and to assay the underlying mechanisms in a Randomized Controlled Trial (RCT).

This study uses a parallel arm RCT design with a 26-week intervention period. We plan to enroll 90 participants (male/diverse/female) living with overweight or obesity, defined as either a Waist-to-Hip Ratio (WHR) ≥ 0.9 (male)/0.85 (diverse, female) or a Body Mass Index (BMI) ≥ 25 kg/m2. Key inclusion criteria are 18-60 years of age and exclusion criteria are type 2 diabetes, psychiatric disease, and Magnetic Resonance Imaging (MRI) contraindications. The interventions comprise either a daily supplementary intake of 30 g soluble fiber (inulin), or weekly neurocognitive behavioral group sessions, compared to placebo (equicaloric maltodextrin). At baseline and follow-up, food decision-making is assessed utilizing task-based MRI. Secondary outcome measures include structural MRI, eating habits, lifestyle factors, personality traits, and mood. Further, we obtain fecal and blood samples to investigate gut microbiome composition and related metabolites.

This study relies on expanding research suggesting that dietary prebiotics could improve gut microbiome composition, leading to beneficial effects on gut-brain signaling and higher-order cognitive functions. In parallel, neurocognitive behavioral interventions have been proposed to improve unhealthy eating habits and metabolic status. However, causal evidence on how these "bottom-up" and "top-down" processes affect food decision-making and neuronal correlates in humans is still scarce. In addition, microbiome, and gut-brain-axis-related mediating mechanisms remain unclear. The present study proposes a comprehensive approach to assess the effects of these gut-brain-related processes influencing food decision-making in overweight and obesity.

ClinicalTrials.gov NCT05353504. Retrospectively registered on 29 April 2022.

Background/Objectives: Television viewing has been linked with increased weight and obesity, likely through decreased physical activity associated with sitting and viewing television, as well as increased intake of food, likely through reduced awareness of eating and intake behaviours. This review sought to determine the effects of television viewing on energy intake relative to the absence of television. Methods: We adhered to the PRISMA guidelines and pre-registered this review in PROSPERO (CRD42023493092). The PICOS strategy included children, adolescents and adults of all ages (P), exposed to television viewing only during meals (I) compared to no television and no other distractors (C), with the outcome as energy intake or consumption (O) for both within-subject and between-subject randomised controlled trial (RCT) designs (S). Results: Robust-variance meta-analyses of k = 57 effect sizes from 23 studies showed no overall effect, noting high heterogeneity. When analyses were limited to television alone with k = 29 effect sizes from 23 studies, we revealed a small significant effect of television viewing on intake (g = 0.13, 95% CI [0.03-0.24]) compared to no television. Moderation analysis showed that television viewing strongly increased intake at the next meal (g = 0.30, 95% CI [0.03-0.57]) but not immediate intake (g = 0.10, 95% CI [-0.01-0.21]). Conclusions: This review showed that television viewing increases food intake, especially at the next meal. This effect was evident across both children and adults. This review highlights how television viewing impacts intake and offers potential avenues for intervention based on our findings.

The cafeteria diet (CAF) is a superior diet model in animal experiments compared with the conventional high-fat diet (HFD), effectively inducing obesity, metabolic disturbances, and multi-organ damage. Nevertheless, its impact on gut microbiota composition during the progression of obesity, along with its repercussions on the enteric nervous system (ENS) and gastrointestinal motility has not been completely elucidated. To gain more insight into the effects of CAF diet in the gut, C57BL/6 mice were fed with CAF or a standard diet for 2 or 8 wk. CAF-fed mice experienced weight gain, disturbed glucose metabolism, dysregulated expression of colonic IL-6, IL-22, TNFα, and TPH1, and altered colon morphology, starting at week 2. Fecal DNA was isolated and gut microbiota composition was monitored by sequencing the V3-V4 16S rRNA region. Sequence analysis revealed that Clostridia and Proteobacteria were specific biomarkers associated with CAF-feeding at week 2, while Bacteroides and Actinobacteria were prominent at week 8. In addition, the impact of CAF diet on ENS was investigated (week 8), where HuC/D+ neurons were measured and counted, and their biophysical properties were evaluated by patch clamp. Gut contractility was tested in whole-mount preparations. Myenteric neurons in CAF-fed mice exhibited reduced body size, incremented cell density, and decreased excitability. The amplitude and frequency of the rhythmic spontaneous contractions in the colon and ileum were affected by the CAF diet. Our findings demonstrate, for the first time, that CAF diet gradually changes the gut microbiota and promotes low-grade inflammation, impacting the functional properties of myenteric neurons and gut contractility in mice.NEW & NOTEWORTHY The gut microbiota changes gradually following the consumption of CAF diet. An increase in Clostridia and Proteobacteria is a hallmark of dysbiosis at the early onset of gut inflammation and obesity. The CAF diet was effective in inducing intestinal low-grade inflammation and alterations in myenteric neuronal excitability in mice. CAF diet is a reliable strategy to study the interplay between gut dysbiosis and low-grade inflammation, in addition to the mechanisms underlying gastrointestinal dysmotility associated with obesity.

The prevalence of overweight and obesity is increasing, leading to metabolic-associated fatty liver disease (MAFLD) characterized by excessive accumulation of liver fat and a risk of developing hepatocellular carcinoma (HCC). The driver gene mutations may play the roles of passengers that occur in single 'hotspots' and can promote tumorigenesis from benign to malignant lesions. We investigated the impact of high body weight and BMI on HCC survival using The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) dataset. To explore the effects of obesity-related gene mutations on HCC, we collected driver mutation genes in 34 TCGA patients with BMI ≥ 27 and 23 TCGA patients with BMI < 27. The digital PCR performing the PBMC samples for the variant rate by clinical cohort of 96 NAFLD patients. Our analysis showed that obesity leads to significantly worse survival outcomes in HCC. Using cbioportal, we identified 414 driver mutation genes in patients with obesity and 127 driver mutation genes in non-obese patients. Functional analysis showed that obese-related genes significantly enriched the regulated lipid and insulin pathways in HCC. The insulin secretion pathway in patients with obesity HCC-specific survival identified ABCC8 and PRKCB as significant genes (p < 0.001). It revealed significant differences in gene mutation and gene expression profiles compared to non-obese patients. The digital PCR test ABCC8 variants were detected in PBMC samples and caused a 14.5% variant rate, significantly higher than that of non-obese NAFLD patients. The study findings showed that the gene ABCC8 was a patient with the obesity-related gene in NAFLD, which provides the probability that ABCC8 mutation contributes to the pre-cancer lesion biomarker for HCC.